Loading quotes...

Forecast

The analysts' average price target is €89.20 (+90.97%). The median is €78.49 (+68.04%).

Buy	7
Hold	0
Sell	0

News Go to news feed

MBX Biosciences hits record high at $69.50

MBX Biosciences stock rose to an all‑time high of $69.50 after a one‑year gain of 414% and a 104% increase year‑to‑date. Six analysts recently raised their earnings estimates, while a fair‑value analysis rates the stock as slightly overvalued. Quarterly results are due in two days; the company recently underwent leadership changes with Steve Hoerter as new chairman and CEO and John Smither named permanent CFO. Phase‑2 data for canvuparatid showed a 57% response rate after one year, but the stock initially fell on the news; Stifel raised its price target to $56 and maintained a "Buy" rating after positive MBX‑4291 data. » More on de.investing.com
MBX Biosciences reaches new all-time high at $66.66

MBX Biosciences stock rose to a new all-time high of $66.66 and is up 336.31% year-to-date; it currently trades at $65.30, about 1% below the 52-week high. InvestingPro values the stock slightly above its fair value. The company announced leadership changes: Steve Hoerter will be chairman and CEO, John Smither permanent CFO, and co-founder Kent Hawryluk resigned. MBX released Phase 2 data on canvuparatid showing annual response rates of 57%, but the stock later fell; Stifel raised its price target to $56 and maintained a buy rating after positive interim data on MBX-4291. » More on de.investing.com
MBX Biosciences: CEO Kent Hawryluk resigns, Steve Hoerter named chairman and CEO

MBX Biosciences shares fell about 8.3% in after-hours trading following the announcement of the leadership change. Steve Hoerter was appointed chairman and chief executive officer effective immediately; Kent Hawryluk resigned as president, CEO and board member. John Smither was promoted from interim to permanent chief financial officer. MBX reaffirmed targets for H2 2026, including a Phase 3 start with Canvuparatid, nomination of a triple GLP-1/GIP/GCGR agonist, and 12-week data for MBX 4291. » More on de.investing.com

Financials

In the last quarter, MBX Biosciences had revenue of €0 and net profit of -€32.5M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-32.5M	97.36%
EBITDA	-35.79M	118.04%

Fundamentals

Metric	Value
Market capitalization	€2.34B
Number of shares	48.16M
52-week high/low	€64.79 - €18.03
Dividends	No
Beta	0.10
P/E ratio	-22.67
PEG ratio	3.89
P/B ratio	6.34
P/S ratio	0.00

Company profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.